As one of the fastest moving biotech startups in Thailand, Baiya Phytopharm Co., Ltd., have employed their expertise in plant biotech for the clinical development and production of products and pharmaceuticals including their flagship product: a first-generation plant-based COVID-19 vaccine.
In cooperation with their mission, the AT Virology Lab operates to employ our own facilities for the determination of the efficacy of their products, particularly their COVID-19 vaccines: Baiya-SARS-CoV-2-Vax 1 and Baiya-SARS-CoV-2-Vax 2.
The VERDI project is a multidisciplinary collaboration across a global network with the objective to advance our knowledge on the epidemiological repercussions of the many variants of SARS-CoV-2, especially among children and pregnant women.
With the shared commitment to improve the understanding of the virus and the disease it causes; along with the joint participation of clinicians, healthcare workers and willing participants, the AT lab acts as one of the nodes of this vast network.
Founded on the genomic work of Mycobacterium tuberculosis in Thailand, the Pornchai Matangkasombut Center for Microbial Genomics (CENMIG) have expanded into covering an extensive range of microorganisms including viruses and other types of bacteria.
In collaboration with CENMIG, the AT Virology Lab has established comprehensive research platforms such as the Pathogen discovery platform, for using Next-generation sequencing (NGS) strategies in uncovering novel and uncommon viral pathogens in clinical samples.